Home › Alcon Laboratories, Inc. › Hydrus® Microstent
Hydrus® Microstent
Alcon Laboratories, Inc. · Model F00022 · UDI-DI 00867487000134
OGO
Prescription
0
510(k) clearances
2,684
Adverse events
4
Recalls
9
Facilities
Description
Hydrus® Microstent
Recalls
| Date | Firm | Reason |
|---|---|---|
| 2018-08-28 | Alcon Research, LTD. | Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) com |
| 2018-08-28 | Alcon Research, LTD. | Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) com |
| 2018-08-28 | Alcon Research, LTD. | Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) com |
| 2018-08-28 | Alcon Research, LTD. | Analysis of the completed dataset from the COMPASS-XT long-term study showed that the CyPass Micro-Stent group experienced statistically significant endothelial cell loss (ECL) com |
Query this across every FDA database — by API.
Linked GUDID · 510(k)/PMA · MAUDE · recalls · establishments. Free tier, no card required.
Get your free API keyRead the docsData compiled from public U.S. FDA sources (GUDID, 510(k)/PMA, MAUDE, recalls, establishment registration). Adverse-event reports are unverified and do not establish causation. Informational only — not medical, clinical, or regulatory advice.